Interview with Chor Eng Cheah, Head of Invidia Malaysia and Singapore, Invida…
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of…
Address: Level 2, No 10 Jalan Bersatu 13/4, 46200 Petaling Jaya, Selangor, Malaysia
Tel: -15028
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality. We do this through our proven brand and sales know-how, strong expertise across a number of key therapeutic categories, and deep experience in all critical Asia Pacific countries. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.
Invida operates in the fastest growing healthcare markets worldwide, increasing at an annual compounded growth rate of 12 percent, more than double the global growth rate for the sector. Today, the Asia Pacific markets represent approximately US$50 billion and 10 percent of worldwide pharmaceutical sales.* With China and India among top growth contributors globally, Invida is currently implementing a long-term strategy to establish itself as a leader in these rapidly expanding markets through targeted investments.
With more than 4,000 employees throughout Asia Pacific, Invida operates throughout the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from biotech and multinational companies. Partnering is a critical component of Invida’s business model.
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
